Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

v3.24.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Mar. 15, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Trading Symbol IKT    
Entity Registrant Name INHIBIKASE THERAPEUTICS, INC.    
Entity Central Index Key 0001750149    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Emerging Growth Company true    
Entity Small Business true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   6,476,844  
Entity Public Float     $ 19.1
Entity Tax Identification Number 26-3407249    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Security Exchange Name NASDAQ    
Documents Incorporated by Reference

None

    
Entity Address, Address Line One 3350 Riverwood Parkway SE    
Entity Address, Address Line Two Suite 1900    
Entity Address, City or Town Atlanta    
Entity Address, State or Province GA    
Entity Address, Postal Zip Code 30339    
City Area Code 678    
Local Phone Number 392-3419    
Entity Incorporation, State or Country Code DE    
Title of 12(b) Security Common Stock, $0.001 par value    
Entity File Number 001-39676    
Auditor Name CohnReznick LLP    
Auditor Firm ID 596    
Auditor Location Holmdel, New Jersey    
Document Financial Statement Error Correction [Flag] false